- Home
- OCUL vs TSHA Comparison
OCUL vs TSHA Comparison
Compare OCUL & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | TSHA |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OCUL | TSHA |
|---|---|---|
| Price | $8.26 | $5.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $23.56 | $11.63 |
| AVG Volume (30 Days) | ★ 2.5M | 2.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | $1,990,000.00 | ★ $9,773,000.00 |
| Revenue This Year | $7.93 | N/A |
| Revenue Next Year | $96.07 | $1,152.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.48 | ★ 17.28 |
| 52 Week Low | $6.23 | $2.25 |
| 52 Week High | $16.44 | $7.30 |
Technical Indicators
Market Signals| Indicator | OCUL | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 42.38 | 43.87 |
| Support Level | $7.62 | $5.27 |
| Resistance Level | $9.93 | $6.01 |
| Average True Range (ATR) | 0.46 | 0.36 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 24.47 | 36.78 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.